BioNano Genomics Stock News

Bionano Genomics (BNGO), a provider of optical genome mapping ((OGM)) solutions, is trading lower in the post-market Tuesday after the company topped analyst forecasts for revenue with…

Bionano Genomics press release (BNGO): Q4 Net Loss -$22.95M, compared to -$11.73M in Q4 2020.Revenue of $6.3M beats by $0.45M.Revenue was $18.0 million for the full year and $6.3…

SAN DIEGO, March 01, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr ® system and provider of N x Clincial™, a leading software solution for visualization, interpretation and reporting of genomic data, today reported financial results for the fourth quarter and full year ended December 31, 2021 and revenue outlook for 2022.

Bionano Genomics' (BNGO) CEO Erik Holmlin on Q4 2021 Results - Earnings Call Transcript

Rare diseases affect more than 350 million people globally It is estimated that 1 in 15 people globally are affected by a rare disease Estimates are that 25 million Americans and 30 million in Europe are living with a rare disease More than 7,000 rare diseases have been identified to date Approximately 80% of rare disease are believed to be caused by genetic factors It takes on average 7 seven years, with standard techniques, to obtain an accurate diagnosis Even after all these standard techniques, more than 50% of patients with rare diseases remain go undiagnosed SAN DIEGO, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO ), pioneer of optical genome mapping (OGM) solutions on the Saphyr ® system and provider of N x Clinical™, the leading software solution for visualization, interpretation and reporting of genomic data, today announced the launch of its rare undiagnosed genetic disease (RUGD) strategic initiative in recognition of Rare Disease Day. There are many different causes of rare disease, but most are genetic and believed to be directly caused by changes in genes or chromosomes.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Bionano Genomics (NASDAQ:BNGO) is a life sciences instrumentation company focused on the genome analysis space. Its products include Saphyr, Bionano Chips, Bionano Prep Kits, and Bionano Data Solutions. Source: Dennis Diatel / Shutterstock.com The firm has discovered research about cancer, genetic diseases, and genome assembly, whereas its clinical research is about Facioscapulohumeral Muscular Dystrophy (FSHD) and…. The post Bionano Genomics Has Attractive Applications But An Unattractive Stock Price appeared first on InvestorPlace . More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Man Who Called Black Monday: “Prepare Now.” Get in Now on Tiny $3 ‘Forever Battery’ Stock Interested in Crypto? Read This First...

SAN DIEGO, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Tuesday, March 1st, 2022 at 4:30 p.m. Eastern

SAN DIEGO, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. ( BNGO ), pioneer of optical genome mapping (OGM) solutions on the Saphyr ® system and provider of N x Clinical, the leading software solution for visualization, interpretation and reporting of genomic data, today announced the publication of a peer-reviewed, prospective study comparing OGM to traditional methods and demonstrating improved sensitivity and lower cost of OGM in the analysis of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) compared to karyotyping and fluorescence in situ hybridization (FISH). This research provides scientific and practical support for the use of OGM workflows as a potential alternative to karyotype and FISH testing for certain hematologic malignancies, while also identifying novel structural variants (SVs) that can impact disease stratification or serve as therapeutic targets. In the study, published in the International Journal of Cancer , 27 samples from subjects with AML or MDS underwent routine cytogenetic diagnostics (karyotype, FISH and RT-PCR when indicated), as well as OGM.

Bionano Genomics Inc. (NASDAQ:BNGO) has a beta value of 1.95 and has seen 6.49 million shares traded in the last trading session. The company, currently valued at $589.90M, closed the last trade at $2.02 per share which meant it lost -$0.02 on the day or -0.98% during that session. The BNGO stock price is -610.4% Bionano Genomics Inc. (BNGO): Why Is The Stock Strong? Read More »

Bionano's Saphyr appears to be able to help doctors treat leukemia more effectively, and adoption of its device is growing rapidly. BNGO stock is a buy.

If Bionano’s (BNGO) optical genome mapping (OGM) system Saphyr is to gain mainstream adoption, it has to show its performance improves on standard of care (SOC) met…

In todays recent session, 1.74 million shares of the Bionano Genomics Inc. (NASDAQ:BNGO) have been traded, and its beta is 1.91. Most recently the companys share price was $2.15, and it changed around -$0.04 or -1.60% from the last close, which brings the market valuation of the company to $676.71M. BNGO at last check was Bionano Genomics Inc. (NASDAQ: BNGO) Shares Might Go Down -84.01% This Year Read More »

SAN DIEGO, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr ® system and provider of N x Clinical, the leading software solution for visualization, interpretation and reporting of genomic data, announced today that company management will present virtually at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference. Erik Holmlin, PhD, Bionanos president and chief executive officer, is scheduled to participate in a fireside chat on Wednesday, February 16th, 2022 at 2:30 pm ET. BTIG hosted events are intended for prospective and existing BTIG clients. To listen to the live event, please contact your BTIG representative with interest.

SAN DIEGO, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of NxClinical™, the leading softwa